{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Myeloproliferative+Neoplasm+%28MPN%29",
    "query": {
      "condition": "Myeloproliferative Neoplasm (MPN)"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 75,
    "total_pages": 8,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Myeloproliferative+Neoplasm+%28MPN%29&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-06-26T08:12:56.060Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05123365",
      "title": "An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Myeloproliferative Neoplasm",
        "MPN",
        "Essential Thrombocythemia",
        "Polycythemia Vera",
        "Myelofibrosis"
      ],
      "interventions": [
        {
          "name": "N-Acetylcysteine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, Irvine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 27,
      "start_date": "2022-01-03",
      "completion_date": "2026-11-15",
      "has_results": false,
      "last_update_posted_date": "2026-03-10",
      "last_synced_at": "2026-06-26T08:12:56.060Z",
      "location_count": 2,
      "location_summary": "Irvine, California • Orange, California",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05123365"
    },
    {
      "nct_id": "NCT04103645",
      "title": "Intra-patient Dose Escalation Study to Investigate Safety and Feasibility of Vactosertib in Treating Anemic MPN Patients",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Myeloproliferative Neoplasm"
      ],
      "interventions": [
        {
          "name": "Vactosertib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Weill Medical College of Cornell University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2019-11-22",
      "completion_date": "2024-07-10",
      "has_results": true,
      "last_update_posted_date": "2025-07-02",
      "last_synced_at": "2026-06-26T08:12:56.060Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04103645"
    },
    {
      "nct_id": "NCT07362225",
      "title": "MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Polycythemia Vera",
        "ET (Essential Thrombocythemia)",
        "Polycythemia Vera (PV)",
        "Essential Thrombocythemia (ET)",
        "Primary Myelofibrosis (MF)",
        "Primary Myelofibrosis (PMF)",
        "Myelofibrosis",
        "Myelofibrosis (MF)",
        "Myelofibrosis, Primary",
        "Myelofibrosis, Post ET",
        "Myelofibrosis, Post PV",
        "Myelofibrosis (PMF)",
        "Myelofibrosis，MF",
        "Myelofibrosis; Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis",
        "Myelofibrosis Due to and Following Polycythemia Vera",
        "Myelofibrosis Transformation in Essential Thrombocythemia",
        "Myelofibrosis With High Molecular Risk Mutations",
        "MF",
        "Secondary Myelofibrosis",
        "Secondary Myelofibrosis in Myeloproliferative Disease",
        "Secondary Myelofibrosis (Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis)",
        "Post-Polycythemia Vera Myelofibrosis",
        "Post-polycythemia Vera Myelofibrosis (PPV-MF)",
        "Post-polycythemia Vera Myelofibrosis (Post-PV MF)",
        "Post-polycythemia Vera Myelofibrosis(Post-PV MF)",
        "Post-PV MF",
        "Post-Essential Thrombocythemia Myelofibrosis",
        "Post-essential Thrombocythemia Myelofibrosis (PET-MF)",
        "Post-essential Thrombocythemia Myelofibrosis(Post-ET MF)",
        "Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)",
        "Post-ET MF",
        "Pre-fibrotic Myelofibrosis",
        "Myeloproliferative Disorder",
        "Myeloproliferative Disorders",
        "Myeloproliferative Disorders (MPD)",
        "Myeloproliferative Neoplasms (MPNs)",
        "Myeloproliferative Neoplasm(MPN)-Associated Myelofibrosis",
        "Myeloproliferative Neoplasm With 10% Blasts or Higher",
        "Myeloproliferative Neoplasms",
        "MPN",
        "MPN (Myeloproliferative Neoplasms)",
        "MPN-associated Myelofibrosis",
        "Myeloproliferative Neoplasm, Unclassifiable",
        "Myeloproliferative Neoplasm, Not Otherwise Specified",
        "Accelerated Phase MPN",
        "Accelerated Phase Myeloproliferative Neoplasm",
        "Blast Phase MPN",
        "Blast Phase Myeloproliferative Neoplasm",
        "Thrombocythemia Myelofibrosis (PET-MF)",
        "Thrombocythemia, Essential",
        "Thrombocythemia, Hemorrhagic",
        "Agnogenic Myeloid Metaplasia",
        "Chronic Idiopathic Myelofibrosis",
        "Idiopathic Myelofibrosis",
        "MDS/MPN Crossover Syndromes"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "MPN Research Foundation",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5000,
      "start_date": "2025-09-26",
      "completion_date": "2035-09-08",
      "has_results": false,
      "last_update_posted_date": "2026-01-23",
      "last_synced_at": "2026-06-26T08:12:56.060Z",
      "location_count": 2,
      "location_summary": "Chicago, Illinois • New York, New York",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07362225"
    },
    {
      "nct_id": "NCT03238248",
      "title": "Pevonedistat and Azacitidine in MDS or MDS/MPN Patients Who Fail Primary Therapy With DNA Methyl Transferase Inhibitors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Myelodysplastic Syndromes",
        "Myeloproliferative Neoplasm"
      ],
      "interventions": [
        {
          "name": "Azacitidine Subcutaneous Injection or Intravenous Infusion",
          "type": "DRUG"
        },
        {
          "name": "Pevonedistat Infusion",
          "type": "DRUG"
        },
        {
          "name": "Bone Marrow Biopsy & Aspirate",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Vanderbilt-Ingram Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 71,
      "start_date": "2017-08-07",
      "completion_date": "2023-11-27",
      "has_results": true,
      "last_update_posted_date": "2024-11-04",
      "last_synced_at": "2026-06-26T08:12:56.060Z",
      "location_count": 5,
      "location_summary": "Miami, Florida • Westwood, Kansas • New York, New York + 2 more",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Westwood",
          "state": "Kansas"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Rochester",
          "state": "New York"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03238248"
    },
    {
      "nct_id": "NCT03287245",
      "title": "A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Idasanutlin Monotherapy in Participants With Hydroxyurea-Resistant/Intolerant Polycythemia Vera",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Polycythemia Vera"
      ],
      "interventions": [
        {
          "name": "Idasanutlin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 27,
      "start_date": "2018-02-21",
      "completion_date": "2020-03-03",
      "has_results": true,
      "last_update_posted_date": "2021-12-08",
      "last_synced_at": "2026-06-26T08:12:56.060Z",
      "location_count": 5,
      "location_summary": "Phoenix, Arizona • Kansas City, Kansas • New York, New York + 2 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Independence",
          "state": "Ohio"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03287245"
    },
    {
      "nct_id": "NCT05467800",
      "title": "Study of Canakinumab in Patients With Myelofibrosis",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Primary Myelofibrosis",
        "Post-essential Thrombocythemia Myelofibrosis",
        "ET-MF",
        "Post-polycythemia Vera Related Myelofibrosis",
        "PV-MF"
      ],
      "interventions": [
        {
          "name": "Canakinumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "John Mascarenhas",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2022-08-02",
      "completion_date": "2027-07-01",
      "has_results": false,
      "last_update_posted_date": "2026-05-07",
      "last_synced_at": "2026-06-26T08:12:56.060Z",
      "location_count": 7,
      "location_summary": "Los Angeles, California • Tampa, Florida • Westwood, Kansas + 4 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Westwood",
          "state": "Kansas"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Charlotte",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05467800"
    },
    {
      "nct_id": "NCT02663518",
      "title": "A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hematologic Malignancies",
        "Solid Tumor"
      ],
      "interventions": [
        {
          "name": "PF-0791800 (TTI-621)",
          "type": "DRUG"
        },
        {
          "name": "PF-07901800 (TTI-621) plus Rituximab",
          "type": "DRUG"
        },
        {
          "name": "PF-07901800 (TTI-621) plus Nivolumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 249,
      "start_date": "2016-01-28",
      "completion_date": "2022-11-23",
      "has_results": true,
      "last_update_posted_date": "2024-05-10",
      "last_synced_at": "2026-06-26T08:12:56.060Z",
      "location_count": 47,
      "location_summary": "Duarte, California • Palo Alto, California • Denver, Colorado + 15 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02663518"
    },
    {
      "nct_id": "NCT02718300",
      "title": "A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "MPN (Myeloproliferative Neoplasms)"
      ],
      "interventions": [
        {
          "name": "Parsaclisib",
          "type": "DRUG"
        },
        {
          "name": "Ruxolitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Incyte Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 74,
      "start_date": "2017-02-08",
      "completion_date": "2022-04-29",
      "has_results": true,
      "last_update_posted_date": "2024-05-01",
      "last_synced_at": "2026-06-26T08:12:56.060Z",
      "location_count": 39,
      "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Berkeley, California + 33 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Berkeley",
          "state": "California"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02718300"
    },
    {
      "nct_id": "NCT03895112",
      "title": "MPN-RC 118 AVID200 in Myelofibrosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Primary Myelofibrosis",
        "Post-essential Thrombocythemia Myelofibrosis",
        "Post-polycythemia Vera Myelofibrosis",
        "Post ET MF",
        "Post PV MF"
      ],
      "interventions": [
        {
          "name": "AVID200",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "John Mascarenhas",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2019-02-15",
      "completion_date": "2022-05-16",
      "has_results": false,
      "last_update_posted_date": "2023-02-10",
      "last_synced_at": "2026-06-26T08:12:56.060Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03895112"
    },
    {
      "nct_id": "NCT06523556",
      "title": "Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Atypical Chronic Myeloid Leukemia",
        "Chronic Myelomonocytic Leukemia",
        "Myelodysplastic/Myeloproliferative Neoplasm",
        "Recurrent Myelodysplastic/Myeloproliferative Neoplasm",
        "Recurrent Myeloproliferative Neoplasm",
        "Refractory Chronic Myelomonocytic Leukemia",
        "Refractory Myelodysplastic/Myeloproliferative Neoplasm",
        "Refractory Myeloproliferative Neoplasm"
      ],
      "interventions": [
        {
          "name": "Axatilimab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Azacitidine",
          "type": "DRUG"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Marrow Aspiration and Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Survey Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "Uma Borate",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 52,
      "start_date": "2024-08-02",
      "completion_date": "2028-10-31",
      "has_results": false,
      "last_update_posted_date": "2026-03-13",
      "last_synced_at": "2026-06-26T08:12:56.060Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06523556"
    }
  ]
}